Boston Scientific stock upgraded to buy as growth is expected to pick up in H2 and next year.

Boston Scientific's stock has fallen over 30% in the past year, underperforming other medical equipment and healthcare stocks in the S&P 500. Despite this, the stock has been upgraded from hold to buy due to expectations of growth accelerating in the second half of the year and expanding further next year. The stock is now attractively valued with a forward price-to-earnings ratio of 20x and a forward free cash flow yield of 4%, making it less overbought compared to its healthcare peers. The recent selling pressure appears excessive, suggesting potential for a rebound.